Zealand Pharma (NASDAQ: ZLDPY; Copenhagen: ZEAL) CEO Adam Steensberg presented Wednesday September 16, 2026 at 11:30 a.m. EDT at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, introducing the company's Metabolic Frontier 2030 strategic plan targeting five commercial products by 2030. The plan anchors on petrelintide (long-acting subcutaneous amylin analog Phase 3 with Roche under an April 2026 exclusive collaboration and licensing agreement; deal terms up to $5.3 billion including $1.65 billion upfront, plus 50/50 profit share on both monotherapy and combination products including petrelintide plus Roche's enicepatide GLP-1/GIP dual agonist). Phase 2 ZUPREME-1 documented up to 10.7% mean weight loss at 42 weeks versus 1.7% placebo, with no vomiting cases and no GI-related discontinuations at the maximally effective dose. Steensberg indicated the next phase of obesity competition may center on tolerability and patient retention rather than only on weight-loss magnitude — a positioning that differentiates petrelintide from the higher-efficacy but higher-GI-burden retatrutide (28% weight loss) and CagriSema. Zealand is building integrated commercial capabilities for petrelintide while relying on partners for other assets in rare disease and inflammation.
Roche (SIX: ROG) is scheduled to hold its investor Pharma Day Monday September 28, 2026, providing updates across the R&D portfolio including three obesity assets that collectively position the company as the credible third-place global obesity competitor behind Eli Lilly and Novo Nordisk. Petrelintide (amylin analog, partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, Phase 3 monotherapy initiation planned late 2026 following ZUPREME-1's 10.7% weight loss at 42 weeks). Enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2). HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties). The Roche Pharma Day coincides with the EASD 2026 Annual Meeting Rome September 28 through October 2, where AstraZeneca will present AZD6234 Phase 2 data, Zealand Pharma will present petrelintide data, and Novo Nordisk will present amycretin and CagriSema updates.
Roche (SIX: ROG) is scheduled to hold its Pharma Day investor event Monday September 28, 2026, providing updates across the R&D portfolio including three top-three-position obesity assets: petrelintide (amylin analog partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, ZUPREME-1 documented 10.7% weight loss at 42 weeks, Phase 3 monotherapy initiation planned late 2026); enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2); and HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties; Genentech takes over from Phase 2 forward). The Pharma Day briefing frames Roche as a credible third-place global obesity competitor behind Eli Lilly (Zepbound-Mounjaro-Foundayo plus upcoming retatrutide) and Novo Nordisk (Wegovy-Ozempic plus CagriSema plus amycretin), with EASD 2026 Rome September 28-October 2 the immediate downstream data catalyst.